Overview
This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
Description
To evaluate the safety for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis.
Eligibility
Inclusion Criteria:
- Those who participated in PMC-P-07 clinical trials and received Cellgram-LC
- Those who voluntarily agreed in writing to participate in this investigation
Exclusion Criteria:
-